Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest

Journal of Medicinal Chemistry

Volumn 47, Issue 14, 2004, Pages 3518-3536

  Dawson, Marcia I ^a   Harris, Danni L ^b   Liu, Gang ^a   Hobbs, Peter D ^c   Lange, Christopher W ^g   Jong, Ling ^c   Bruey Sedano, Nathalie ^a   James, Sharon Y ^a   Zhang, Xiao Kun ^a   Peterson, Valerie J ^d   Leid, Mark ^d   Farhana, Lulu ^e,f   Rishi, Arun K ^e   Fontana, Joseph A ^e,f  

^a BURNHAM INSTITUTE   (United States)

^b MOLECULAR RESEARCH INSTITUTE   (United States)

^c SRI INTERNATIONAL   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g Discovery Partners International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 3 (3' ACETAMIDOPROPYLOXY)CINNAMIC ACID; 6 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 2 NAPHTHALENECARBOXYLIC ACID; 6 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 5 CHLORONAPHTHALENECARBOXYLIC ACID; ADAMANTANE DERIVATIVE; CELL NUCLEUS RECEPTOR; CHLORINE; FUNCTIONAL GROUP; HYDROGEN; NUCLEAR RECEPTOR NUR77; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROTEIN P21; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR GAMMA; RETINOID; UNCLASSIFIED DRUG;

ALPHA HELIX; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CHEMICAL BOND; CONTROLLED STUDY; DENSITY FUNCTIONAL THEORY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; MATHEMATICAL COMPUTING; MITOSIS INHIBITION; MOLECULAR DYNAMICS; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION;

ADAMANTANE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING, COMPETITIVE; CELL DIVISION; CELL LINE, TUMOR; CINNAMATES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NAPHTHALENES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 3042548151     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030524k     Document Type: Article

References (119)

1. Bernard, B. A.; Bernardon, J. M.; Delescluse, C.; Martin, B.; Lenoir, M. C.; Maignan, J.; Charpentier, B.; Pilgrim, W. R.; Reichert, U.; Shroot, B. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem. Biophys. Res. Commun. 1992, 186, 977-983.
2. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995, 11, 493-504.
3. WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res. 1996, 56, 5055-5062.
4. Fontana, J. A.; Dawson, M. I.; Leid, M.; Rishi, A. K.; Zhang, Y.; Hsu, C.-A.; Lu, J. S.; Peterson, V. J.; Jong, L.; Hobbs, P.; Chao, W.-R.; Shroot, B.; Reichert, U. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int. J. Cancer 2000, 86, 474-479.
5. Dawson, M. I.; Hobbs, P. D.; Peterson, V. J.; Leid, M.; Lange, C. W.; Feng, K. C.; Chen, G.; Gu, J.; Li, H.; Kolluri, S. K.; Zhang, X.; Zhang, Y.; Fontana, J. A. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 2001, 61, 4723-4730.
6. Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. The retinoid receptors. In The Retinoids: Biology, Chemistry, and Medicine; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994; pp 319-349.
7. Dawson, M. I.; Chao, W. R.; Pine, P.; Jong, L.; Hobbs, P. D.; Rudd, C. K.; Quick, T. C.; Niles, R. M.; Zhang, X.-K.; Lombardo, A.; Ely, K. R.; Shroot, B.; Fontana, J. A. Correlation of retinoid binding affinity to RARα with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res. 1995, 55, 4446-4451.
8. Fitzgerald, P.; Teng, M.; Chandraratna, R. A. S.; Heyman, R. A.; Allegretto, E. A. Retinoic acid receptor α expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res. 1997, 57, 2642-2650.
9. Chao, W. R.; Hobbs, P. D.; Jong, L.; Zhang, X.-K.; Zheng, Y.; Wu, Q.; Shroot, B.; Dawson, M. I. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH:OVCAR-3 ovarian cancer cell line in culture. Cancer Lett. 1997, 115, 1-7.
10. Li, H.; Kolluri, S. K.; Gu, J.; Dawson, M. I.; Cao, X.; Hobbs, P. D.; Lin, B.; Chen, G.; Lu, J.; Lin, F.; Xie, Z.; Fontana, J. A.; Reed, J. C.; Zhang, X. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000, 289, 1159-1164.
11. Milbrandt, J. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron 1988, 1, 183-188.
12. Chang, C.; Kokontis, J. Identification of a new member of the steroid receptor super-family by cloning and sequence analysis. Biochem. Biophys. Res. Commun. 1988, 155, 971-977.
13. Hazel, T. G.; Nathans, D.; Lau, L. F. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 8444-8448.
14. Leid, M.; Kastner, P.; Lyons, R.; Nakshatri, H.; Saunders: M.; Zacharewski, T.; Chen, J.-Y.; Staub, A.; Garnier, J.-M.; Mader, S.; Chambon, P. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992, 68, 377-395.
15. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science 1998, 281, 1309-1312.
16. Lin, B.; Kolluri, S. K.; Lin, F.; Liu, W.; Han, Y. H.; Cao, X.; Dawson, M. I.; Reed, J. C.; Zhang, X.-K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116, 527-540.
17. Armstrong, R. B.; Ashenfelter, K. O.; Eckhoff, C.; Levin, A. A.; Shapiro, S. S. General and reproductive toxicology of retinoids. In The Retinoids: Biology, Chemistry, and Medicine; Sporn, M. B., Roberts, A. B., Goodman, D. S., Eds.; Raven Press: New York, 1994; pp 545-572.
18. Graf, N.; Riesinger, P.; Reinhard, H. Retinoids in the treatment of acute promyelocytic leukemia. Review of the literature. Klin. Padiatr. 1995, 207, 43-47.
19. Selleri, C.; Pane, F.; Notaro, R.; Catalano, L.; Santoro, L. E.; Luciano, L.; Frigeri, F.; Salvatore, F.; Rotoli, B. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Br. J. Haematol. 1996, 92, 937-940.
20. De Botton, S.; Dombret, H.; Sanz, M.; Miguel, J. S.; Caillot, D.; Zittoun, R.; Gardembas, M.; Stamatoulas, A.; Conde, E.; Guerci, A.; Gardin, C.; Geiser, K.; Makhoul, D. C.; Reman, O.; de la Serna, J.; Lefrere, F.; Chomienne, C.; Chastang, C.; Degos, L.; Fenaux, P. Incidence, clinical features, and outcome of all transretinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998, 92, 2712-2718.
21. Levi, I.; Raanani, P.; Shalmon, B.; Schiby-Brilliant, R.; Ben-Bassat, I. Acute neutrophilic dermatosis induced by all-transretinoic acid treatment for acute promyelocytic leukemia. Leuk. Lymphoma 1999, 34, 401-404.
22. Wu, W.; Sun, G.; Zhou, R.; Li, X.; Shen, Z.; Wang, Z. The relationship between the levels of granulocyte colony-stimulating factor and leukocytosis induced by all-trans retinoic acid in acute promyelocytic leukemia. Chin. Med. J. (Engl.) 1999, 112, 1085-1087.
23. Tommasino, C.; De Felice, L.; Colombo, S.; Salaris, D.; Capocasa, T.; Giudici, D. Retinoic acid syndrome. Severe respiratory insufficiency treated with CPAP. Minerva Anestesiol. 2000, 66, 555-559.
24. Duvic, M.; Hymes, K.; Heald, P.; Breneman, D.; Martin, A. G.; Myskowski, P.; Crowley, C.; Yocum, R. C. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J. Clin. Oncol. 2001, 19, 2456-2471.
25. Martín del Pozo, M.; Cisneros de la Fuente, E.; Solano, F.; Martin, M. L.; de la Serna, J. The retinoic acid syndrome, a complication of acute promyelocytic leukemia therapy. An. Med. Intern. 2001, 18, 195-200.
26. Goncalves, A.; Camerlo, J.; Bun, H.; Gravis, G.; Genre, D.; Bertucci, F.; Resbeut, M.; Pech-Gourg, F.; Durand, A.; Maraninchi, D.; Viens, P. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-α in squamous cell carcinoma: Clinical results and pharmacokinetics. Anticancer Res. 2001, 21, 1431-1437.
27. Khuri, F. R.; Rigas, J. R.; Figlin, R. A.; Gralla, R. J.; Shin, D. M.; Munden, R.; Fox, N.; Huyghe, M. R.; Kean, Y.; Reich, S. D.; Hong, W.-K. Multi-institutional Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced nonsmall-cell lung cancer. J. Clin. Oncol. 2001, 19, 2626-2637.
28. Park, C. J.; Bae, Y. D.; Choi, J. Y.; Heo, P. S.; Lee, K. S.; Park, Y. S.; Lee, J. A. Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J. Intern. Med. 2001, 16, 218-221.
29. Shin, D. M.; Glisson, B. S.; Khuri, F. R.; Clifford, J. L.; Clayman, G.; Benner, S. E.; Forastiere, A. A.; Ginsberg, L.; Liu, D.; Lee, J. J.; Myers, J.; Goepfert, H.; Lotan, R.; Hong, W. K.; Lippman, S. M. Phase II and biologic study of interferon α, retinoic acid, and cisplatin in advanced squamous skin cancer. J. Clin. Oncol. 2002, 20, 364-370.
30. Standeven, A. M.; Teng, M.; Chandraratna, R. A. S. Lack of involvement of retinoic acid receptor α in retinoid-induced skin irritation in hairless mice. Toxicol. Lett. 1997, 92, 231-240.
31. Iulianella, A.; Lohnes, D. Contribution of retinoic acid receptor γ to retinoid-induced craniofacial and axial defects. Dev. Dyn. 1997, 209, 92-104.
32. Look, J.; Landwehr, J.; Bauer, F.; Hoffmann, A. S.; Bluethmann, H.; LeMotte, P. Marked resistance of RARγ-deficient mice to the toxic effects of retinoic acid. Am. J. Physiol. 1995, 269, E91-E98.
33. Reczek, P. R.; Ostrowski, J.; Yu, K. L.; Chen, S.; Hammer, L.; Roalsvig, T.; Starrett, J. E., Jr.; Driscoll, J. P.; Whiting, G.; Spinazze, P. G. Role of retinoic acid receptor γ in the Rhino mouse and rabbit irritation models of retinoid activity. Skin Pharmacol. 1995, 8, 292-299.
34. Sheikh, M. S.; Shao, Z.-M.; Li, X.-S.; Dawson, M. I.; Jetten, A. M.; Wu, S.; Conley, B. A.; Garcia, M.; Rochefort, H.; Fontana, J. A. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-α acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem. 1994, 269, 21440-21447.
35. Swisshelm, K.; Ryan, K.; Lee, X.; Tsou, H. C.; Peacocke, M.; Sager, R. Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 1994, 5, 133-141.
36. Li, X.-S.; Shao, Z.-M.; Sheikh, M. S.; Eiseman, J. L.; Sentz, D.; Jetten, A. M.; Chen, J.-C.; Dawson, M. I.; Aisner, S.; Rishi, A. K.; Fontana, J. A. Retinoic acid nuclear receptor β (RARβ) inhibits breast carcinoma anchorage independent growth. J. Cell. Physiol. 1995, 165, 449-458.
37. Lotan, R.; Xu, X. C.; Lippman, S. M.; Ro, J. Y.; Lee, J. S.; Lee, J. J.; Hong, W.-K. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin. New Engl. J. Med. 1995, 332, 1405-1410.
38. Liu, Y.; Lee, M.-O.; Wang, H.-G.; Li, Y.; Hashimoto, Y.; Klaus, M.; Reed, J. C.; Zhang, X. RARβ mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 1996, 16, 1138-1149.
39. Zhang, Y.; Dawson, M. I.; Mohammad, R.; Rishi, A. K.; Farhana, L.; Feng, K. C.; Leid, M.; Peterson, V.; Zhang, X.-K.; Edelstein, M.; Eilander, D.; Biggar, S.; Wall, N.; Reichert, U.; Fontana, J. A. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analogue. Blood 2002, 100, 2917-2925.
40. Zhang, Y.; Dawson, M. I.; Ning, Y.; Polin, L.; Parchment, R. E.; Corbett, T.; Mohamed, A. N.; Feng, K. C.; Farhana, L.; Rishi, A. K.; Hogge, D.; Leid, M.; Peterson, V. J.; Zhang, X.-K; Mohammad, R.; Lu, J. S.; Willman, C.; VanBuren, E.; Biggar, S.; Edelstein, M.; Eilender, D.; Fontana, J. A. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analogue. Blood 2003, 102, 3743-3752.
41. Schiff, L. J.; Okamura, W. H.; Dawson, M. I.; Hobbs, P. D. Structure-biological activity relationships of new synthetic retinoids on epithelial differentiation of cultured hamster trachea. In Chemistry and Biology of Synthetic Retinoids; Dawson, M. I., Okamura, W. H., Eds.; CRC Press: Boca Rotan, 1990; pp 302-363.
42. Dawson, M. I.; Chan, R. L.-S.; Derdzinski, K.; Hobbs, P. D.; Chao, W.-R.; Schiff, L. J. Synthesis and pharmacological activity of 6-[(E)-2-(2,6,6- trimethyl-1-cyclohexen-1-yl)ethen-1-yl]- and 6-(1,2,3,4-tetrahydro-1,1,4,4- tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acids. J. Med. Chem. 1983, 26, 1653-1656.
43. Schiff, L. J.; Moore, S.J.; Dawson, M. I.; Hobbs, P. D.; Chan, R. L.-S.; Derdzinski, K. Biological activity of aromatic retinoid acid analogues in hamster tracheal organ culture. In In Vitro Models of Respiratory Epithelium; Schiff, L. J., Ed.; CRC Press: Boca Raton, FL, 1986; pp 51-83.
44. Cincinelli, R.; Dallavalle, S.; Merlini, L.; Penco, S.; Pisano, C.; Carminati, P.; Giannini, G.; Vesci, L.; Gaetano, C.; Illy, B.; Zuco, V.; Supino, R.; Zunino, F. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J. Med. Chem. 2003, 46, 909-912.
45. Dawson, M. I.; Chao, W.-R.; Hobbs, P. D.; Delair, T. The inihibitory effects of retinoids on the induction of ornithine decarboxylase and the promotion of tumors in mouse epidermis. In Chemistry and Biology of Synthetic Retinoids; Dawson, M. I., Okamura, W. H., Eds.; CRC Press: Boca Rotan, 1990; pp 385-466.
46. Dawson, M. I.; Park, J.-H.; Chen, G.; Chao, W.; Dousman, L.; Waleh, N.; Hobbs, P. D.; Jong, L.; Toll, L.; Zhang, X.; Gu, J.; Agadir, A.; Merchant, J. L.; Bai, L.; Verma, A. K.; Thacher, S. M.; Chandraratna, R. A. S.; Shroot, B.; Hill, D. L. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: A potential role for trans-RA-induced ZBP-89 in ODC inhibition. Int. J. Cancer 2001, 91, 8-21.
47. Dawson, M. I.; Hobbs, P. D.; Stein, R. B.; Berger, T. S.; Heyman, R. A. Interaction of retinoids with retinoic nuclear receptor isoforms. In Retinoids: New Trends in Research and Clinical Applications; Livrea, M. A., Packer, L., Eds.; Marcel Dekker: New York, 1992; pp 205-221.
48. Lehmann, J. M.; Dawson, M. I.; Hobbs, P. D.; Husmann, M.; Pfahl, M. Identification of retinoids with nuclear receptor subtype-selective activities. Cancer Res. 1991, 51, 4804-4809.
49. Dawson, M. I.; Zhang, X.; Hobbs, P. D.; Jong, L. Synthetic retinoids and their usefulness in biology and medicine. In Vitamin A and Retinoids: An Update of Biological Aspects and Clinical Applications; Livrea, M. A., Ed.; Birkhäuser Verlag: Basel, Switzerland, 2000; pp 161-196.
50. Lehmann, J. M.; Jong, L.; Fanjul, A.; Cameron, J. F.; Liu, X. P.; Haefner, P.; Dawson, M. I.; Pfahl, M. A novel class of retinoids, selective for retinoid X receptor response pathways. Science 1992, 258, 1944-1946.
51. Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W.-R.; Pfahl, M.; Lee, M.-O.; Shroot, B. Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. J. Med. Chem. 1995, 38, 3368-3383.
52. Dawson, M. I.; Cameron, J. F.; Hobbs, P. D.; Jong, L.; Pfahl, M.; Zhang, X.; Lehmann, J. M. (SRI International and The Burnham Institute, formerly La Jolla Cancer Research Foundation). Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors. U.S. Patent 5, 837,725, 1998.
53. Dawson, M. I.; Hobbs, P. D.; Jong, L.; Xiao, D.; Chao, W.-R.; Pan, C.; Zhang, X.-K. sp2-bridged diaryl retinoids: Effects of bridge-region substitution on retinoid X receptor (RXR) selectivity. Bioorg. Med. Chem. Lett. 2000, 10, 1307-1310.
54. Dawson, M. I.; Zhang, X.-K. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogues of all-trans-retinoic acid and 9-cis-retinoic acid. Curr. Med. Chem. 2002, 9, 623-637.
55. Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, J. A.; Heyman, R. A.; Nadzan, A. M. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 1995, 38, 3146-3155.
56. Beard, R. L.; Colon, D. F.; Song, T. K.; Davies, P. J.; Kochhar, D. M.; Chandraratna, R. A. S. Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogues of retinoic acid. J. Med. Chem. 1996, 39, 3556-3563.
57. 3 and a novel apoptosis-inducing retinoid on breast cancer and endothelial cell growth. Cancer Lett. 1998, 133, 1-8.
58. Robertson, K. A.; Emami, B.; Collins, S. J. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992, 80, 1885-1889.
59. Ota, E.; Shimozawa, J. T. Substitution reactions of phenanthrols. XII. Conversion of phenanthrols to the corresponding chloro- and bromophenanthrenes and their dipole moment measurements. Nippon Kagaku Kaishi 1987, 4, 757-761.
60. Dawson, M. I.; Cavasotto, C. N.; Hobbs, P. D.; Jong, L.; Feng, K.-C.; Lui, H.; Abagyan, R.; Zhang, X. Synthesis and biological activity of an RXR antagonist. Presented at the 93rd Annual AACR National Meeting, San Francisco, CA, 2002.
61. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J.-A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
62. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4618.
63. Delabre, K.; Guiochon-Mantel, A.; Milgrom, E. In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4421-4425.
64. Brand, C.; Ségard, P.; Plouvier, P.; Formstecher, P.; Danzé, P. M.; Lefebvre, P. Selective alteration of gene expression in response to natural and synthetic retinoids. BMC Pharmacol. 2002, 2, 13.
65. Klaholz, B. P.; Renaud, J. P.; Mitschler, A.; Zusi, C.; Chambon, P.; Gronemeyer, H.; Moras, D. Conformational adaptation of agonists to the human nuclear receptor RARγ. Nat. Struct. Biol. 1998, 5, 199-202.
66. Apfel, C.; Bauer, F.; Crettaz, M.; Forni, L.; Kamber, M.; Kaufmann, F.; LeMotte, P.; Pirson, W.; Klaus, M. A retinoic acid receptor α antagonist selectively counteracts retinoic acid effects. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7129-7133.
67. Lala, D. S.; Mukherjee, R.; Schulman, I. G.; Koch, S. S.; Dardashti, L. J.; Nadzan, A. M.; Croston, G. E.; Evans, R. M.; Heyman, R. A. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 1996, 383, 450-453.
68. Arulmozhiraja, S.; Selvin, P. C.; Fujii, T. Structures, potential energy curves, and torsional barrier heights for selected polychlorinated biphenyls: A density functional theory study. J. Phys. Chem. A 2002, 106, 1765-1769.
69. Arulmozhiraja, S.; Fujii, T. Torsional barrier, ionization potential, and electron affinity of biphenyl - A theoretical study. J. Chem. Phys. 2001, 115, 10589-10594.
70. Peterson, V. J.; Barofsky, E.; Deinzer, M. L.; Dawson, M. I.; Feng, K. C.; Zhang, X.-K.; Madduru, M. R.; Leid, M. Mass-spectrometric analysis of agonist-induced retinoic acid receptor γ conformational change. Biochem. J. 2002, 362, 173-181.
71. Dawson, M. I.; Hobbs, P. D.; Derdzinski, K. A.; Chao, W.-R.; Frenking, G.; Loew, G. H.; Jetten, A. M.; Napoli, J. L.; Williams, J. B.; Sani, B. P.; Wille, J. J., Jr.; Schiff, L. J. Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids. J. Med. Chem. 1989, 32, 1504-1517.
72. Nielsen, L. L.; Dell, J.; Maxwell, E.; Armstrong, L.; Maneval, D.; Catino, J. J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 1997, 4, 129-138.
73. Sheikh, M. S.; Li, X.-S.; Chen, J. C.; Shao, Z. M.; Ordonez, J. V.; Fontana, J. A. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 1994, 9, 3407-3415.
74. Xinarianos, G.; Liloglou, T.; Prime, W.; Sourvinos, G.; Karachristos, A.; Gosney, J. R.; Spandidos, D. A.; Field, J. K. p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in nonsmall cell lung carcinoma. Int. J. Cancer 2002, 101, 248-252.
75. Campling, B. G.; el-Deiry, W. S. Clinical implications of p53 mutations in lung cancer. Methods Mol. Med. 2003, 75, 53-77.
76. Zhang, Y.; Huang, Y.; Rishi, A. K.; Sheikh, M. S.; Shroot, B.; Reichert, U.; Dawson, M. I.; Poirer, G.; Fontana, J. A. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp. Cell Res. 1999, 247, 233-240.
77. Li, Y.; Lin, B.; Agadir, A.; Liu, R.; Dawson, M. I.; Reed, J. C.; Fontana, J. A.; Bost, F.; Hobbs, P. D.; Zheng, Y.; Chen, G.-Q.; Shroot, B.; Mercola, D.; Zhang, X.-K. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol. Cell. Biol. 1998, 18, 4719-4731.
78. White, E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996, 10, 1-15.
79. Green, D.; Kroemer, G. The central executioners of apoptosis: Caspases or mitochondria? Trends Cell. Biol. 1998, 8, 267-271.
80. L expression and its down-regulation by a novel retinoid in breast carcinoma cells. Exp. Cell Res. 1997, 232, 17-24.
81. Fanjul, A. N.; Piedrafita, F. J.; Al-Shamma, H.; Pfahl, M. Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. Cancer Res. 1998, 58, 4607-4610.
82. Rishi, A. K.; Sun, R. J.; Gao, Y.; Hsu, C. K.; Gerald, T. M.; Saeed Sheikh, M.; Dawson, M. I.; Reichert, U.; Shroot, B.; Fornace, A. J., Jr.; Brewer, G.; Fontana, J. A. Posttranscriptional regulation of the DNA damage-inducible gadd45 gene in human breast carcinoma cells exposed to a novel retinoid CD437. Nucleic Acids Res. 1999, 27, 3111-3119.
83. Lu, X. P.; Fanjul, A.; Picard, N.; Pfahl, M.; Rungta, D.; Nared-Hood, K.; Carter, B.; Piedrafita, J.; Tang, S.; Fabbrizio, E. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat. Med. 1997, 3, 686-690.
84. Sun, S.-Y.; Yue, P.; Shroot, B.; Hong, W. K.; Lotan, R. Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells. Oncogene 1999, 18, 3894-3901.
85. Sun, S.-Y.; Yue, P.; Wu, G. S.; El-Deiry, W. S.; Shroot, B.; Hong, W. K.; Lotan, R. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. 1999, 59, 2829-2833.
86. Sun, S.-Y.; Yue, P.; Chen, X.; Hong, W. K.; Lotan, R. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res. 2002, 62, 2430-2436.
87. Hsu, C. A.; Rishi, A. K.; Li, X.-S.; Gerald, T. M.; Dawson, M. I.; Schiffer, C.; Reichert, U.; Shroot, B.; Poirer, G. C.; Fontana, J. A. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997, 89, 4470-4479.
88. Gianni, M.; de Thé, H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARα protein and the PML retargeting on PML-nuclear bodies. Leukemia 1999, 13, 739-749.
89. Mologni, L.; Ponzanelli, I.; Bresciani, F.; Sardiello, G.; Bergamaschi, D.; Gianni, M.; Reichert, U.; Rambaldi, A.; Terao, M.; Garattini, E. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999, 93, 1045-1061.
90. Oridate, N.; Higuchi, M.; Suzuki, S.; Shroot, B.; Hong, W.-K.; Lotan, R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437). Int. J. Cancer 1997, 70, 484-487.
91. Wan, X.; Duncan, M. D.; Nass, P.; Harmon, J. W. Synthetic retinoid CD437 induces apoptosis of esophageal squamous HET-1A cells through the caspase-3-dependent pathway. Anticancer Res. 2001, 21, 2657-2663.
92. Adachi, H.; Adams, A.; Hughes, F. M.; Zhang, J.; Cidlowski, J. A.; Jetten, A. M. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways. Cell Death Differ. 1998, 5, 973-983.
93. Schadendorf, D.; Worm, M.; Jurgovsky, K.; Dippel, E.; Reichert, U.; Czarnetzki, B. M. Effects of various synthetic retinoids on proliferation and immunophenotype of human melanoma cells in vitro. Recent Results Cancer Res. 1995, 139, 183-193.
94. Schadendorf, D.; Kern, M. A.; Artuc, M.; Pahl, H. L.; Rosenbach, T.; Fichtner, I.; Nurnberg, W.; Stuting, S.; von Stebut, E.; Worm, M.; Makki, A.; Jurgovsky, K.; Kolde, G.; Henz, B. M. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J. Cell Biol. 1996, 135, 1889-1898.
95. Meister, B.; Fink, F. M.; Hittmair, A.; Marth, C.; Widschwendter, M. Antiproliferative activity and apoptosis induced by retinoic acid receptor-γ selectively binding retinoids in neuroblastoma. Anticancer Res. 1998, 18, 1777-1786.
96. Langdon, S. P.; Rabiasz, G. J.; Ritchie, A. A.; Reichert, U.; Buchan, P.; Miller, W. R.; Smyth, J. F. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother. Pharmacol. 1998, 42, 429-432.
97. Holmes, W. F.; Soprano, D. R.; Soprano, K. J. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J. Cell Biochem. 2003, 89, 262-278.
98. Holmes, W. F.; Soprano, D. R.; Soprano, K. J. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J. Biol. Chem. 2002, 277, 45408-45419.
99. Hsu, J. Y.; Pfahl, M. ET-1 expression and growth inhibition of prostate cancer cells: A retinoid target with novel specificity. Cancer Res. 1998, 58, 4817-4822.
100. Liang, J. Y.; Fontana, J. A.; Rao, J. N.; Ordonez, J. V.; Dawson, M. I.; Shroot, B.; Wilber, J. F.; Feng, P. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate 1999, 38, 228-236.
101. Lu, X. P.; Fanjul, A.; Picard, N.; Shroot, B.; Pfahl, M. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int. J. Cancer 1999, 80, 272-278.
102. Ponzanelli, I.; Gianni, M.; Giavazzi, R.; Garofalo, A.; Nicoletti, I.; Reichert, U.; Erba, E.; Rambaldi, A.; Terao, M.; Garattini, E. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalenecarboxylic acid. Blood 2000, 95, 2672-2682.
103. Lovat, P. E.; Ranalli, M.; Bernassola, F.; Tilby, M.; Malcolm, A. J.; Pearson, A. D.; Piacentini, M.; Melino, G.; Redfern, C. P. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int. J. Cancer 2000, 88, 977-985.
104. Lovat, P. E.; Ranalli, M.; Bernassola, F.; Tilby, M.; Malcolm, A. J.; Pearson, A. D.; Piacentini, M.; Melino, G.; Redfern, C. P. Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. Med. Pediatr. Oncol. 2000, 35, 663-668.
105. Costantini, P.; Jacotot, E.; Decaudin, D.; Kroemer, G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. 2000, 92, 1042-1053.
106. Marchetti, P.; Mortier, L.; Beauvillain, V.; Formstecher, P. Are mitochondria targets of anticancer drugs responsible for apoptosis? Ann. Biol. Clin. (Paris) 2002, 60, 391-403.
107. Buehler, C. A.; Harris, J. O.; Shacklett, C.; Block, B. P. The action of formaldehyde on m-hydroxybenzoic acid. II. J. Am. Chem. Soc. 1946, 68, 574-577.
108. Kelly, K. G.; Ellenbogen, L. Histidine decarboxylase inhibiting 4-bromo-3-hydroxy-hippuric acid. Ger. Patent 2,062,611, 1971.
109. 1A receptor antagonists for the treatment of benign prostatic hyperplasia. J. Med. Chem. 2000, 43, 2703-2718.
110. Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham, T. E., III.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vicent, J. J.; Crowley, M.; Tsui, V.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. AMBER6. University of California, San Francisco, 1999.
111. Ciccotti, G.; Ryckaert, J. P. Molecular dynamics simulation of rigid molecules. Comput. Phys. Rep. 1986, 3, 345.
112. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: Applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
113. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
114. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
115. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. J. Phys. Chem. 1993, 97, 10269-10280.
116. Charpentier, B.; Bernardon, J. M.; Eustache, J.; Millois, C.; Martin, B.; Michel, S.; Shroot, B. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 1995, 38, 4993-5006.
117. Sakashita, A.; Kizaki, M.; Pakkala, S.; Schiller, G.; Tsuruoka, N.; Tomosaki, R.; Cameron, J. F.; Dawson, M. I.; Koeffler, H. P. 9-cis-retinoic acid: Effects on normal and leukemic hematopoiesis in vitro. Blood 1993, 81, 1009-1016.
118. Zhang, X.-K.; Hoffmann, B.; Tran, P. B.; Graupner, G.; Pfahl, M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 1992, 355, 441-446.
119. Wu, Q.; Dawson, M. I.; Zheng, Y.; Hobbs, P. D.; Agadir, A.; Jong, L.; Li, Y.; Liu, R.; Lin, B.; Zhang, X.-K. Inhibition of transretinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol. Cell. Biol. 1997, 17, 6598-6608.